Two Novartis Phase III studies show twice as many Ph+ CML patients achieve deeper levels of response with Tasigna® compared to Glivec® - MarketWatch
*just copy & paste
p/s : Good news to patient of CML..but comfirm to used or still on trial??
Hopely there can find cure of this sickness (^_^) pray for it.
